Clinical Trials

Adenocarcinoma, Stomach Neoplasms

NCT07431281 2026-05-27

Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2

Phase 3 Recruiting

2,130 enrolled

Phase 2 Not yet recruiting

Adenocarcinoma Of Esophagus, Adenocarcinoma, Esophageal Neoplasms, Stomach Neoplasms

NCT07574541 2026-05-27

Multitargeted Recombinant Ad5 PSA/MUC-1/Brachyury-Based Immunotherapy (TriAdeno) Vaccine With IL-15 Superagonist N-803 in Participants With Clinically Localized Prostate Cancer Undergoing Active Surveillance

52 enrolled

Phase 3 Active not recruiting

Adenocarcinoma, Carcinoma, Neoplasms, Neoplasms by Histologic Type, Neoplasms, Glandular and Epithelial, Prostatic Neoplasms

NCT05581121 2026-05-26

PAROLA

Phase 3 Recruiting

510 enrolled

Gynecologic

Adenocarcinoma, Uterine Cervical Neoplasms, Carcinoma, Adenosquamous

NCT06564844 2026-05-22

TROPION-Lung12

25 enrolled

Thoracic

Adenocarcinoma, Carcinoma, Non-Small-Cell Lung

NCT07489820 2026-05-22

AAPICO

Phase NA Not yet recruiting

100 enrolled

Phase 3 Not yet recruiting

Adenocarcinoma

NCT07598032 2026-05-20

iCCaRE

200 enrolled

Adenocarcinoma, Prostatic Neoplasms

NCT07196488 2026-05-19

Dyadic Co-learning Intervention for Patients With Prostate Cancer and Their Spouses

Phase NA Recruiting

60 enrolled

Adenocarcinoma, Prostatic Neoplasms

NCT00911118 2026-05-18

Dose Escalation Study Using Ultra-Hypofractionated, Image-Guided, Intensity-Modulated Radiotherapy in Prostate Cancer

Phase 1 Completed

120 enrolled

Phase 1 Not yet recruiting

Adenocarcinoma, Prostatic Neoplasms

NCT07316686 2026-05-18

Lutécio

18 enrolled

Adenocarcinoma, Prostatic Neoplasms

NCT07541911 2026-05-18

LaserSAFE

Phase NA Recruiting

693 enrolled

Phase 2 Not yet recruiting

Margins of Excision, Adenocarcinoma, Prostatic Neoplasms

NCT07592910 2026-05-18

MOMENT

60 enrolled

Adenocarcinoma, Prostatic Neoplasms

NCT02133196 2026-05-13

T Cell Receptor Immunotherapy for Patients With Metastatic Non-Small Cell Lung Cancer

85 enrolled

Thoracic

Adenocarcinoma, Carcinoma, Non-Small-Cell Lung, Carcinoma, Squamous Cell, Lung Neoplasms, Neoplasm Metastasis, Carcinoma, Adenosquamous

NCT04379596 2026-05-13

DG-03

450 enrolled

Phase 2 Active not recruiting

Adenocarcinoma, Carcinoma, Esophageal Neoplasms, Stomach Neoplasms

NCT05208944 2026-05-13

THIO Sequenced With Cemiplimab in Advanced NSCLC

227 enrolled

Thoracic

Adenocarcinoma, Carcinoma, Non-Small-Cell Lung, Carcinoma, Squamous Cell, Carcinoma, Large Cell

NCT03415854 2026-05-12

NABPLAGEMD

Phase 2 Completed

34 enrolled 11 charts

Adenocarcinoma, Pancreatic Neoplasms

NCT05672524 2026-05-12

A Study of Tucatinib and Trastuzumab in People With Rectal Cancer

37 enrolled

Adenocarcinoma, Rectal Neoplasms

NCT05968326 2026-05-11

IMCODE003

260 enrolled

Adenocarcinoma

NCT06794073 2026-05-11

Efficacy and Safety of Multimodal Ablation Combined With PD-1 Monoclonal Antibody, Lenvatinib and TACE in the Treatment of Unresectable Primary Hepatocellular Carcinoma: A Single-Arm, Single-Center Clinical Study

Phase NA Recruiting

17 enrolled

Phase 1 Active not recruiting

Adenocarcinoma, Digestive System Neoplasms, Carcinoma, Hepatocellular, Liver Neoplasms, Neoplasms, Glandular and Epithelial

NCT04627246 2026-05-08

Personalized Vaccine With SOC Chemo Followed by Nivo in Pancreatic Cancer

14 enrolled

Phase 1 Active not recruiting

Adenocarcinoma, Neoplasms

NCT04644770 2026-05-08

A Study of JNJ-69086420, an Actinium-225-Labeled Antibody Targeting Human Kallikrein-2 (hK2) for Advanced Prostate Cancer

144 enrolled

Adenocarcinoma, Prostatic Neoplasms

NCT04864067 2026-05-08

NOAHS-ARC

Phase 2 Completed

39 enrolled

Phase 1/2 Not yet recruiting

Adenocarcinoma, Rectal Neoplasms

NCT07529808 2026-05-08

ChefHat-001

164 enrolled

Phase 1 Active not recruiting

Adenocarcinoma, Colonic Neoplasms, Gastrointestinal Neoplasms, Neoplasms, Pancreatic Neoplasms, Stomach Neoplasms

NCT03132922 2026-05-07

MAGE-A4ᶜ¹º³²T for Multi-Tumor

71 enrolled 20 charts

DermatologicGastrointestinalGenitourinaryGynecologicHead & NeckSarcomaThoracic

Adenocarcinoma, Urinary Bladder Neoplasms, Carcinoma, Non-Small-Cell Lung, Esophageal Neoplasms, Head and Neck Neoplasms, Melanoma, Neoplasm Metastasis, Ovarian Neoplasms, Sarcoma, Stomach Neoplasms, Sarcoma, Synovial, Liposarcoma, Myxoid

NCT05922930 2026-05-06

Study of TROP2 CAR Engineered IL15-transduced Cord Blood-derived NK Cells Delivered Intraperitoneally for the Management of Platinum Resistant Ovarian Cancer, Mesonephric-like Adenocarcinoma, and Pancreatic Cancer

Phase 1/2 Recruiting

51 enrolled

GastrointestinalGynecologic

Adenocarcinoma, Ovarian Neoplasms, Pancreatic Neoplasms

NCT06205836 2026-05-06

Cemiplimab With or Without Fianlimab to Treat Older Patients With Localized or Locally Advanced MSI-H Colorectal Cancer

44 enrolled

Phase 2 Not yet recruiting

Adenocarcinoma, Carcinoma, Colorectal Neoplasms

NCT07281768 2026-05-06

Capecitabine/Oxaliplatin Chemotherapy and Cemiplimab With or Without Fianlimab or REGN7075 in Locally Advanced Rectal Cancer

66 enrolled

Adenocarcinoma, Carcinoma, Rectal Neoplasms, Colorectal Neoplasms

NCT07568444 2026-05-06

Enhancing Readability of Lay Abstracts and Summaries for Medical Knowledge Using Generative Artificial Intelligence (BRIDGE AI 3)

Phase 2 Completed

120 enrolled

GastrointestinalGynecologic

Adenocarcinoma, Urinary Bladder Neoplasms, Kidney Neoplasms, Prostatic Neoplasms, Testicular Neoplasms

NCT04034251 2026-05-05

Intraperitoneal and Intravenous Paclitaxel Chemotherapy With Oral Capecitabine for Gastric Adenocarcinoma With Peritoneal Carcinomatosis

Phase 2 Terminated

12 enrolled 18 charts

Adenocarcinoma, Peritoneal Neoplasms, Stomach Neoplasms

NCT05365581 2026-05-05

A Study of ASP2138 Given by Itself or Given With Other Cancer Treatments in Adults With Stomach Cancer, Gastroesophageal Junction Cancer, or Pancreatic Cancer

Phase 1 Recruiting

398 enrolled

Phase 3 Active not recruiting

Adenocarcinoma

NCT03504397 2026-05-04

Spotlight

565 enrolled 63 charts 1 FDA